Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
13th Oct 200611:30 amRNSPossible Acquisition
13th Oct 200611:30 amRNSSuspension - Kiotech Int
29th Sep 20064:56 pmRNSInterim Results - Correction
27th Sep 20067:00 amRNSInterim Results
5th Sep 20062:46 pmRNSDirectorate Change
23rd Aug 20069:10 amRNSDiv currency conversion rate
22nd Aug 200610:28 amRNSDoc re. Interim Report
21st Aug 20069:11 amRNSDirector/PDMR Shareholding
18th Aug 20061:57 pmRNSDirector/PDMR Shareholding
10th Aug 200611:27 amRNSDirector/PDMR Shareholding
7th Aug 200610:20 amRNSDirector/PDMR Shareholding
31st Jul 20068:00 amRNSInterim Results
28th Jul 200611:00 amRNSDirectorate Change
12th Jul 200611:00 amRNSTrading Statement
3rd Jul 20067:00 amRNSChange of Adviser
19th Jun 20064:57 pmRNSNotice of AGM
7th Jun 20063:05 pmRNSDirector/PDMR Shareholding
6th Jun 20067:01 amRNSFinal Results
5th Jun 20064:23 pmRNSChange in registered office
16th May 20063:48 pmRNSDirectorate Change
16th May 20063:44 pmRNSDirectorate Change
10th May 20063:02 pmRNSDirector/PDMR Shareholding
10th May 20062:52 pmRNSChanges to Board
9th May 20061:11 pmRNSDirector/PDMR Shareholding
8th May 20062:55 pmRNSDividend Declaration
8th May 20062:50 pmRNSDirector/PDMR Shareholding
5th May 20064:09 pmRNSDirector/PDMR Shareholding
28th Apr 20062:23 pmRNSDirector/PDMR Shareholding
28th Apr 20062:01 pmRNSDirector/PDMR Shareholding
26th Apr 20064:00 pmRNSAnooraq-Anglo Plats Project
19th Apr 20062:00 pmRNSDirector/PDMR Shareholding
12th Apr 20063:09 pmRNSRhodium Contract Sales
12th Apr 20062:00 pmRNSStatement re. Anglo Platinum
29th Mar 200612:04 pmRNSResults of AGM
20th Mar 20062:00 pmRNSDirector/PDMR Shareholding
15th Mar 200610:00 amRNSCurrency conversion rate
23rd Feb 20069:00 amRNSDirectorate Change
13th Feb 20067:15 amRNSResults of Subsidiary
13th Feb 20067:01 amRNSKola licences agreed
13th Feb 20067:00 amRNSFinal Results
19th Jan 200612:04 pmRNSTrading Statement
10th Jan 200612:21 pmRNSBlocklisting Interim Review
10th Jan 200612:11 pmRNSBlocklisting Interim Review
6th Jan 200612:01 pmRNSAdditional Listing
20th Dec 20059:26 amRNSDirector/PDMR Shareholding
15th Dec 200510:00 amRNSPool agreement at Marikana
30th Nov 20054:30 pmRNSIssue of Options
24th Oct 20054:25 pmRNSDirector/PDMR Shareholding
30th Sep 20057:03 amRNSInterim Results
30th Sep 20057:01 amRNSRapala Deal and Board Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.